非转移性去势抵抗性前列腺癌的当前治疗格局
The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer.
作者信息
El-Amm Joelle, Aragon-Ching Jeanny B
机构信息
Hematology and Oncology, Lebanese American University, Beirut, Lebanon.
Genitourinary (GU) Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA.
出版信息
Clin Med Insights Oncol. 2019 Mar 7;13:1179554919833927. doi: 10.1177/1179554919833927. eCollection 2019.
Abstract
Non-metastatic castration-resistant prostate cancer (nmCRPC) is a heterogeneous disease with variable potential in developing into overt metastases. It is an area of increased unmet need in advanced prostate cancer and for which there had been no great treatments until recent US Food and Drug Administration (FDA) approval of 2 novel anti-androgens apalutamide and enzalutamide, which were both approved given benefit in metastasis-free survival. Early data on the use of darolutamide, another novel anti-androgen, are also explored. This review discusses the pivotal trials that led to the approval of apalutamide and enzalutamide in the nmCRPC setting and discusses the key promises and challenges with the use of these agents.
摘要
非转移性去势抵抗性前列腺癌（nmCRPC）是一种异质性疾病，发展为明显转移的潜力各不相同。它是晚期前列腺癌中未满足需求不断增加的领域，直到美国食品药品监督管理局（FDA）最近批准了两种新型抗雄激素药物阿帕他胺和恩杂鲁胺，在此之前一直没有有效的治疗方法，这两种药物均因在无转移生存期方面的获益而获批。文中还探讨了另一种新型抗雄激素药物达罗他胺的早期使用数据。本综述讨论了促使阿帕他胺和恩杂鲁胺在nmCRPC治疗中获批的关键试验，并讨论了使用这些药物的主要前景和挑战。
相似文献
1
The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer.
Clin Med Insights Oncol. 2019 Mar 7;13:1179554919833927. doi: 10.1177/1179554919833927. eCollection 2019.
2
Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Adv Ther. 2023 Mar;40(3):1087-1103. doi: 10.1007/s12325-022-02389-7. Epub 2022 Dec 26.
3
Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.
Cancer Med. 2023 Feb;12(3):3176-3179. doi: 10.1002/cam4.5189. Epub 2022 Aug 31.
4
Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs.
Res Rep Urol. 2022 Sep 29;14:339-350. doi: 10.2147/RRU.S360444. eCollection 2022.
5
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.
Cancer Manag Res. 2019 Aug 1;11:7253-7262. doi: 10.2147/CMAR.S165706. eCollection 2019.
6
Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Curr Treat Options Oncol. 2019 Feb 11;20(2):14. doi: 10.1007/s11864-019-0611-z.
7
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
Cancers (Basel). 2022 Mar 31;14(7):1792. doi: 10.3390/cancers14071792.
8
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.
Ther Adv Med Oncol. 2020 Dec 23;12:1758835920978134. doi: 10.1177/1758835920978134. eCollection 2020.
9
Darolutamide For Castration-Resistant Prostate Cancer.
Onco Targets Ther. 2019 Oct 23;12:8769-8777. doi: 10.2147/OTT.S197244. eCollection 2019.
10
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
Urol Oncol. 2020 Nov;38(11):826-834. doi: 10.1016/j.urolonc.2020.03.022. Epub 2020 Jun 28.
引用本文的文献
1
Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review.
Curr Oncol Rep. 2024 Nov;26(11):1511-1519. doi: 10.1007/s11912-024-01614-6. Epub 2024 Oct 25.
2
Cancer research in Lebanon: Scope of the most recent publications of an academic institution (Review).
Oncol Lett. 2024 Jun 3;28(2):350. doi: 10.3892/ol.2024.14484. eCollection 2024 Aug.
3
Low-Dose Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Case Report.
Cureus. 2024 Feb 14;16(2):e54197. doi: 10.7759/cureus.54197. eCollection 2024 Feb.
4
Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice.
Front Oncol. 2024 Jan 23;13:1266369. doi: 10.3389/fonc.2023.1266369. eCollection 2023.
5
Longitudinal change in castration-resistant prostate cancer biomarker AST/ALT ratio reflects tumor progression.
Sci Rep. 2023 Sep 15;13(1):15292. doi: 10.1038/s41598-023-42711-z.
6
Crafting a Personalized Prognostic Model for Malignant Prostate Cancer Patients Using Risk Gene Signatures Discovered through TCGA-PRAD Mining, Machine Learning, and Single-Cell RNA-Sequencing.
Diagnostics (Basel). 2023 Jun 7;13(12):1997. doi: 10.3390/diagnostics13121997.
7
Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review.
Front Endocrinol (Lausanne). 2023 Apr 11;13:1125838. doi: 10.3389/fendo.2022.1125838. eCollection 2022.
8
Antiandrogenic Effects of a Polyphenol in through Inhibition of Androgen Synthetic Pathway and Downregulation of Androgen Receptor in Prostate Cancer Cell Lines.
Int J Mol Sci. 2022 Nov 18;23(22):14356. doi: 10.3390/ijms232214356.
9
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study.
BJUI Compass. 2022 May 18;3(5):383-391. doi: 10.1002/bco2.158. eCollection 2022 Sep.
10
Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer.
PLoS One. 2022 May 20;17(5):e0263291. doi: 10.1371/journal.pone.0263291. eCollection 2022.
本文引用的文献
1
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
2
Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
N Engl J Med. 2018 Jun 28;378(26):2458-2460. doi: 10.1056/NEJMp1805966.
3
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.
4
Cancer statistics, 2018.
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
5
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26.
6
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10.
7
Darolutamide (ODM-201) for the treatment of prostate cancer.
Expert Opin Pharmacother. 2017 Jun;18(9):945-952. doi: 10.1080/14656566.2017.1329820. Epub 2017 May 24.
8
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
J Clin Oncol. 2017 Jun 10;35(17):1952-1964. doi: 10.1200/JCO.2017.72.8030. Epub 2017 Apr 25.
9
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Biomed Res Int. 2016;2016:4083183. doi: 10.1155/2016/4083183. Epub 2016 Jul 14.
10
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6.
Zotero 插件